Reported about 9 hours ago
Novavax's shares jumped over 10% after the FDA approved its COVID-19 vaccine, Nuvaxovid, but with limitations for older adults and at-risk individuals. Despite facing delays and setbacks compared to mRNA rivals like Moderna and Pfizer, Novavax anticipates commercial delivery of the vaccine in the U.S. this fall in partnership with Sanofi, contingent on future strain recommendations.
Source: YAHOO